These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 35643206)

  • 1. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    Yoo S; Kim JY; Lim YS; Han S; Choi J
    J Hepatol; 2022 Oct; 77(4):939-946. PubMed ID: 35643206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
    J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
    J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
    Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
    Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma.
    Sohn W; Paik YH; Kim JM; Kwon CH; Joh JW; Cho JY; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Ann Surg Oncol; 2014 Jul; 21(7):2429-35. PubMed ID: 24619495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
    J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
    Gounder PP; Bulkow LR; Snowball M; Negus S; Spradling PR; Simons BC; McMahon BJ
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1197-207. PubMed ID: 27061300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Jang JW; Kim JS; Kim HS; Tak KY; Nam H; Sung PS; Bae SH; Choi JY; Yoon SK; Roberts LR
    Clin Mol Hepatol; 2021 Jan; 27(1):207-218. PubMed ID: 33317255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.
    Anderson RT; Choi HSJ; Lenz O; Peters MG; Janssen HLA; Mishra P; Donaldson E; Westman G; Buchholz S; Miller V; Hansen BE
    Clin Gastroenterol Hepatol; 2021 Mar; 19(3):463-472. PubMed ID: 32473348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
    Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
    J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
    Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
    Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
    Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
    J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
    Park YM; Lee SG
    World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Batrla-Utermann R; Wang LY; You SL; Hsiao CK; Chen PJ; Chen CJ;
    Gut; 2014 Oct; 63(10):1648-57. PubMed ID: 24225939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection.
    Schemmer P; Burra P; Hu RH; Hüber CM; Loinaz C; Machida K; Vogel A; Samuel D
    Liver Int; 2022 Feb; 42(2):288-298. PubMed ID: 34846790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance.
    Cheung KS; Mak LY; Lam LK; Fung J; Liu F; Seto WK; Yuen MF
    Hepatol Int; 2021 Aug; 15(4):881-891. PubMed ID: 33988834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
    Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.